Figure 1.

Kaplan–Meier plot of progression-free survival on larotrectinib (per IRC) and time to progression on the previous line of therapy (per investigator assessment) for (A) the overall dataset (locally advanced or metastatic disease (n = 72)) and (B) patients with metastatic disease (n = 53). For TTP, one patient was censored at 122 months and one patient had progressed at 151 months. Abbreviations: IRC, independent review committee; PFS, progression-free survival; TTP, time to progression.